Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9BRB3
UPID:
PIGQ_HUMAN
Alternative names:
N-acetylglucosamyl transferase component GPI1; Phosphatidylinositol-glycan biosynthesis class Q protein
Alternative UPACC:
Q9BRB3; A2IDE1; D3DU52; O14927; Q96G00; Q96S22; Q9UJH4
Background:
The Phosphatidylinositol N-acetylglucosaminyltransferase subunit Q, also known as N-acetylglucosamyl transferase component GPI1 or Phosphatidylinositol-glycan biosynthesis class Q protein, plays a crucial role in the biosynthesis of glycosylphosphatidylinositol (GPI). This process is fundamental for the attachment of proteins to cell membranes, impacting various cellular functions.
Therapeutic significance:
The protein is directly linked to Multiple congenital anomalies-hypotonia-seizures syndrome 4, a severe disorder marked by early-onset refractory seizures, developmental delays, and multiple anomalies. Understanding the role of Phosphatidylinositol N-acetylglucosaminyltransferase subunit Q could open doors to potential therapeutic strategies for this syndrome.